Literature DB >> 25808416

Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies.

Inês Cardoso1, Jorunn Stamnaes1, Jan Terje Andersen1, Gerry Melino2,3, Rasmus Iversen1, Ludvig M Sollid1.   

Abstract

Transglutaminases have been implicated in various human diseases. A prominent example is the involvement of transglutaminase 2 (TG2) in the gluten-sensitive enteropathy celiac disease, where the enzyme is both the target of autoantibodies and responsible for the generation of immunogenic gluten epitopes. Here, we aimed to characterize the microenvironment of TG2 in the extracellular matrix (ECM) in order to gain insights into the antigenic structures that are recognized by autoantibodies in celiac disease. A panel of TG2-specific mAbs established from gut plasma cells of celiac disease patients was employed as probes to characterize the interactions between TG2 and ECM constituents. With immunofluorescence staining, microplate protein-binding and surface plasmon resonance assays, we found that the main epitope (epitope 1) recognized by TG2-specific gut plasma cells overlaps with the fibronectin (FN)-binding site of TG2. Furthermore, we found that the same TG2 amino acids that are involved in binding of epitope 1 mAbs are also important for efficient binding of FN. Notably, epitope 1 mAbs recognize TG2 in tissue sections, suggesting that some TG2 in the extracellular matrix has interaction partners in addition to FN. We demonstrate that collagen VI is a strong candidate, on the basis of its tissue expression pattern and ability to bind TG2. Collagen VI may thus serve as a matrix for deposition of TG2 in a context that can also be recognized by epitope 1-targeting autoantibodies.
© 2015 FEBS.

Entities:  

Keywords:  celiac disease autoantibodies; collagen VI; extracellular matrix; fibronectin; transglutaminase

Mesh:

Substances:

Year:  2015        PMID: 25808416     DOI: 10.1111/febs.13276

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  8 in total

Review 1.  Immunogenetic Pathogenesis of Celiac Disease and Non-celiac Gluten Sensitivity.

Authors:  Celia Escudero-Hernández; Amado Salvador Peña; David Bernardo
Journal:  Curr Gastroenterol Rep       Date:  2016-07

Review 2.  The matrix in cancer.

Authors:  Thomas R Cox
Journal:  Nat Rev Cancer       Date:  2021-02-15       Impact factor: 60.716

3.  Epitope-dependent Functional Effects of Celiac Disease Autoantibodies on Transglutaminase 2.

Authors:  Kathrin Hnida; Jorunn Stamnaes; M Fleur du Pré; Simon Mysling; Thomas J D Jørgensen; Ludvig M Sollid; Rasmus Iversen
Journal:  J Biol Chem       Date:  2016-10-26       Impact factor: 5.157

4.  Strong Clonal Relatedness between Serum and Gut IgA despite Different Plasma Cell Origins.

Authors:  Rasmus Iversen; Omri Snir; Maria Stensland; José E Kroll; Øyvind Steinsbø; Ilma R Korponay-Szabó; Knut E A Lundin; Gustavo A de Souza; Ludvig M Sollid
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

5.  Dermatan sulfate is a player in the transglutaminase 2 interaction network.

Authors:  Grzegorz Wisowski; Ewa M Koźma; Tomasz Bielecki; Adam Pudełko; Krystyna Olczyk
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

6.  Identification of Isopeptides Between Human Tissue Transglutaminase and Wheat, Rye, and Barley Gluten Peptides.

Authors:  Barbara Lexhaller; Christina Ludwig; Katharina Anne Scherf
Journal:  Sci Rep       Date:  2020-05-04       Impact factor: 4.379

7.  Transglutaminase 2 limits the extravasation and the resultant myocardial fibrosis associated with factor XIII-A deficiency.

Authors:  Kathryn J Griffin; Laura M Newell; Kingsley R Simpson; Cora M L Beckers; Mark J Drinkhill; Kristina F Standeven; Lih T Cheah; Siiri E Iismaa; Peter J Grant; Christopher L Jackson; Richard J Pease
Journal:  Atherosclerosis       Date:  2019-12-17       Impact factor: 5.162

8.  Propofol Suppresses Microglia Inflammation by Targeting TGM2/NF-κB Signaling.

Authors:  Yuanyuan Hou; Xi Xiao; Wei Yu; Sihua Qi
Journal:  J Immunol Res       Date:  2021-08-24       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.